Treatment of Intractable Neurogenic Cough with Cricopharyngeal Myotomy

Anne Lee Durstenfeld, BS  
*Thomas Jefferson University, anne.lee@jefferson.edu*

Joseph Spiegel, MD  
*Thomas Jefferson University, Joseph.Spiegel@jefferson.edu*

Mauritis Boon, MD  
*Thomas Jefferson University, Maurits.Boon@jefferson.edu*

---

**Let us know how access to this document benefits you**

Follow this and additional works at: [http://jdc.jefferson.edu/otograndrounds](http://jdc.jefferson.edu/otograndrounds)

Part of the Otolaryngology Commons

---

**Recommended Citation**

Lee Durstenfeld, BS, Anne; Spiegel, MD, Joseph; and Boon, MD, Mauritis, "Treatment of Intractable Neurogenic Cough with Cricopharyngeal Myotomy" (2013). *Department of Otolaryngology - Head and Neck Surgery Faculty, Presentations and Grand Rounds*. Presentation 14.  
http://jdc.jefferson.edu/otograndrounds/14
Treatment of Intractable Neurogenic Cough with Cricopharyngeal Myotomy

Anne Lee Durstenfeld, BS; Joseph Spiegel, MD1; Maurits Boon, MD1
Thomas Jefferson University, Department of Otolaryngology

INTRODUCTION

Chronic cough is a challenging diagnostic and therapeutic entity due to its multiple etiologies. For patients whose cough does not improve with appropriate treatment for common causes, a neuropathic etiology can be considered. This characteristic symptom complex is typically longstanding, has trigger phenomena, is preceded by tickle sensations in the throat, and produces paroxysms of unproductive cough.1 Bastian et al, who proposed these diagnostic criteria, posit that vagal neuropathy manifested as laryngeal hyperexcitability or hypersensitivity may be the cause. Some success has been reported regarding management with anticonvulsants and antidepressants as well as botulinum toxin injections.1,4 However, some cases may be refractory to such treatments. In this report, we describe 3 patients diagnosed with neurogenic cough who had incomplete response to medical therapy and were identified as having a trigger at the cricopharyngeus. All 3 patients underwent cricopharyngeal myotomy (CPM) with successful resolution of cough.

METHODS

A retrospective chart review was performed for three patients who underwent cricopharyngeal myotomy for intractable cough. Trigger phenomena, previous evaluation and treatment, and outcomes after surgery were assessed and documented. Outcome measures included use of medication after surgery and patient perception of improvement.

RESULTS

Table 1 shows the characteristics of the three cases. All were women aged 61-62 who had suffered from unproductive paroxysms of non-productive coughing for 15-22 years. Each had also been found to have an elevated upper esophageal sphincter pressure on manometry (mean: 184 mmHg, range: 125-219 mmHg). None had obtained lasting relief from cough after trials of anti-allergy, anti-reflux, and more traditional therapies. Incomplete or temporary relief was experienced from neuromodulatory medications and esophageal dilation. Two had experienced temporary improvement for 6 months after botulinum toxin injection into the cricopharyngeus. Subsequent cricopharyngeal myotomy was performed in all patients. All noted symptomatic improvement and were weaned off medication. Continued improvement was noted at follow up, with a mean length of 22 months (range: 7-36 months).

Table 1. Characteristics of patients.

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of cough</td>
<td>15 years</td>
<td>21 years</td>
</tr>
<tr>
<td>PMH</td>
<td>Sinusitis.</td>
<td>Sinusitis, GERD s/p fundoplication.</td>
</tr>
<tr>
<td>Smoking Hx</td>
<td>10 PY</td>
<td>10 PY</td>
</tr>
<tr>
<td>Manometry</td>
<td>Increased UES, increased LES resting pressures</td>
<td>Increased UES, decreased LES resting pressures</td>
</tr>
<tr>
<td>pH measurement</td>
<td>No evidence of GERD</td>
<td>No evidence of GERD</td>
</tr>
<tr>
<td>Reflex medication</td>
<td>Failed Protonix</td>
<td>Failed Protonix</td>
</tr>
<tr>
<td>Allergy medication</td>
<td>Failed Zyrtec</td>
<td>Failed Advair, Singular, Clarinex</td>
</tr>
<tr>
<td>Neuropathic pain medications</td>
<td>Failed Amitriptyline, nortriptyline, Lyrica</td>
<td>Failed nortriptyline, gabapentin, and Lyrica (AED)</td>
</tr>
<tr>
<td>Dilution</td>
<td>Once</td>
<td>Once</td>
</tr>
<tr>
<td>Botulinum toxin</td>
<td>3 times</td>
<td>Once</td>
</tr>
<tr>
<td>Surgery</td>
<td>2010</td>
<td>2011</td>
</tr>
<tr>
<td>Meds after myotomy</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

REFERENCES


DISCUSSION

In the majority of patients, systematic evaluation and optimal therapy will lead to successful resolution of chronic cough.3 However, in patients for whom thorough work-up and empirical treatment have not produced a solution, several models have been described. These include irritable larynx syndrome, sensory laryngeal neuropathic cough, and post-viral vagal neuropathy, which fall under the newly coined umbrella term of chronic cough hypersensitivity syndrome.4 Just as other neuropathies may manifest as paralysis or hypersensitivity to stimuli, vagal neuropathy may present as dysphonia, dysphagia, paresis, pain, laryngospasm, or cough. Neuropathy of motor branches may lead to symptoms of dysphagia and dysphonia while that of sensory branches produces pain and decreased cough threshold.

Bastian et al proposed criteria for a sensory neuropathic model of intractable persistent cough, including irritable cervical and laryngeal sensations, severe attacks of non-productive cough that may be triggered or occur spontaneously, and exclusion criteria based on psychogenic factors such as secondary gain and abrupt onset or resolution. Based on this model, 75% of their patients were treated successfully with amitriptyline.1 By treating paroxysmal chronic cough as a neuropathic pain disorder, Lee and Woo were able to achieve symptomatic relief in 68% of patients using gabapentin, while Van de Kerkhove et al used gabapentin to decrease cough severity in 20 of 35 patients.4 A randomized controlled trial by Ryan et al showed clinically and statistically significant improvement with gabapentin in 84% of patients compared to 40% on placebo; however, cough returned after cessation of therapy.5 Chu et al attributed the decreased threshold for cough stimulation and increased laryngeal tone to hyperexcitable sensory and motor pathways and aimed to inhibit neurogenic inflammation and hyperexcitability using botulinum toxin injection of the thyroarytenoid muscles. They reported complete resolution of cough in a case series of 4 patients.5

In this paper, we report on the use of open cricopharyngeal myotomy to treat chronic cough. The rationale behind targeting the cricopharyngeus came from the observation that these patients identified a trigger at the approximate level of the cricopharyngeus and had elevated UES resting pressures on manometry. Additionally, each had previously obtained improvement in cough from dilation and/or botulinum toxin injection of the UES, which can be considered alternatives to cricopharyngeal myotomy. However, relief was self-limited and therefore cricopharyngeal myotomy was offered as a possible permanent solution. Notably, all patients experienced marked improvement. Our experience with cricopharyngeal myotomy suggests that successful treatment of neuropathic cough can be achieved by relieving pharyngeal hyperexcitability in select patients. The recent literature on endoscopic cricopharyngeal myotomy suggests that the technique may also be a viable consideration for this population. However, this would require further study.

CONCLUSION

In conclusion, cricopharyngeal myotomy may be an alternative treatment for chronic cough in patients for whom work-up is negative and medical management, dilation, and botulinum toxin have failed to provide long-term relief. However, further study is warranted in this patient population to support this assertion.